Healthcare Industry News: Keryx Biopharmaceuticals
News Release - July 21, 2010
Keryx Biopharmaceuticals, Inc. Announces Appointment of Joseph Feczko, M.D. to Board of Directors
NEW YORK, July 21 (Healthcare Sales & Marketing Network) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX ) today announced the appointment of Joseph Feczko, M.D. to the Company's Board of Directors."We are very pleased to have Dr. Feczko join our board of directors," said Michael P. Tarnok, Chairman of the Board. "Dr. Feczko brings to our Board nearly 30 years of global pharmaceutical industry experience in Clinical Development, Regulatory Affairs and Licensing, and we believe that his expertise will be invaluable as we continue to develop our drug candidates with the hope of getting them to those patients that can benefit from them."
Dr. Feczko is currently chairman of the board of directors of Cardoz Pharmaceuticals AB. Additionally, Dr. Feczko is a member of the Board of Directors of the Foundation for the National Institutes of Health, Research!America and the International Longevity Center as well as the New York Academy of Medicine. He is also a member of the Board of Directors of the Accordia Global Health Foundation and the Technical Expert Committee for Trachoma on the International Trachoma Initiative of the Task Force for Global Health, as well as a member of the governing board of the Technology Strategy Board of the United Kingdom.
ABOUT Keryx Biopharmaceuticals, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
Source: Keryx Biopharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
